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ABSTRACT
When in a patient more than one tumour in the same or 
a different organ is diagnosed, multiple primary tumours 
may be present. For epidemiological studies, different 
definitions of multiple primaries are used with the two 
main definitions coming from the project Surveillance 
Epidemiology and End Results and the International 
Association of Cancer Registries and International 
Agency for Research on Cancer. The differences in the 
two definitions have to be taken into consideration when 
reports on multiple primaries are analysed. In this review, 
the literature on multiple primaries is reviewed and 
summarised. Overall, the frequency of multiple primaries is 
reported in the range of 2–17%.
Aetiological factors that may predispose patients to 
multiple primaries can be grouped into host related, 
lifestyle factors and environmental influences. Some of 
the most common cancer predisposition syndromes based 
on a clinical presentation are discussed and the relevant 
genetic evaluation and testing are characterised.
Importantly, from a clinical standpoint, clinical situations 
when multiple primaries should be suspected and ruled 
out in a patient are discussed.
Furthermore, general principles and possible 
treatment strategies for patients with synchronous and 
metachronous multiple primary tumours are highlighted.
INTRODUCTION
Significant progress has been made in the 
prevention, diagnosis and treatment of 
malignant tumours.1 As a result of screening 
programmes and improvement in diagnostic 
procedures, cancer can be detected at an 
earlier stage. Significant treatment advances 
have led to increased overall survival in 
patients with advanced cancer. As of early 
2014, nearly 14.5 million people were alive 
in the USA with a history of cancer. Some of 
these people are on active anticancer therapy, 
others have been diagnosed and treated many 
years ago with no current evidence of tumour. 
For Switzerland, an estimate reported 2.08% 
of cancer survivors in 1990 with an expected 
increase to 3.7% in 2010.2
The fact that patients may have multiple 
primary tumours is not new and already in 
1921 a report found in 3000 cases of malig-
nancy ‘4.7% of cases of multiple growth’.3 
In epidemiological studies, the frequency of 
multiple primaries is reported to be in the 
range of 2–17%.4–8 Many factors can influence 
the reported numbers of multiple primaries, 
namely the definition that was applied (see 
below), the follow-up time since the longer 
patients are followed up after a primary 
cancer diagnosis, the higher the likelihood 
that they may develop a second malignancy 
and importantly also the patient population 
studied.9
Today, the situation of patients with 
multiple primaries is of increasing relevance 
and importance. Apart from many reports in 
the literature on the frequency of multiple 
primaries, the practical implications of the 
management of patients with multiple prima-
ries are rarely discussed. When in a patient two 
active malignancies are diagnosed at the same 
time, the challenge is to find an anticancer 
therapy strategy that covers both cancer 
types without increased toxicity or relevant 
pharmacological interactions and without 
negative impact on the overall outcome. In 
a patient with a previous cancer history and 
potentially prior anticancer therapy, it can be 
difficult to establish the diagnosis of an addi-
tional primary because, for example, newly 
developed metastases could have developed 
from the first cancer diagnosis but could also 
be part of a second malignancy. In daily clin-
ical practice, it is important to recognise these 
situations and to perform the adequate inves-
tigations because of relevant implications 
on subsequent therapeutic management 
strategies. Multiple primaries also impact 
enrolment in clinical research protocols 
because patients with a prior cancer history 
or with current active secondary malignancy 
are generally excluded on most clinical trials.
This review will discuss and summarise the 
topic of multiple primary tumours from an 
epidemiological viewpoint and will review 
some of the large cohort studies on multiple 
primaries. Aetiological factors and genetic 
syndromes predisposing for multiple prima-
ries will be discussed. Furthermore, clinical 
situations when a treating physician should 
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take the possibility of multiple primaries into consider-
ation will be highlighted.
DEFINITION OF MULTIPLE PRIMARIES
Multiple primaries are defined as more than one synchro-
nous or metachronous cancer in the same individual. 
For epidemiological studies, tumours are considered 
multiple primary malignancies if arising in different sites 
and/or are of a different histology or morphology group. 
This avoids misclassification of multifocal/multicentric 
tumours or metastases as multiple primaries. A cancer 
is classified as index cancer if there has been no prior 
record of invasive cancer.10
The definitions and understanding of a multiple primary 
have changed over the time and may differ from one study 
to another. The two most common definitions currently 
used are provided by the Surveillance Epidemiology and 
End Results (SEER) project and the International Associ-
ation of Cancer Registries and International Agency for 
Research on Cancer (IACR/IARC).4 One of the main 
differences is that according to IACR/IARC, several 
groups of topography codes of International Classifica-
tion of Diseases for Oncology 3rdEdition (ICD-O-3) are 
considered one site in the definition of multiple primaries 
(IARC 2004). For example, the colon is regarded as one 
site while the SEER considers single tumours of different 
parts of the colon as single tumours. Further differences 
are that IACR/IARC apply much broader histological 
groups and rules not being time dependent. The use 
of the different guidelines can result in numbers which 
are different by several percentage points (eg, for breast 
or colon cancer). European cancer registries generally 
prefer the use of the IACR/IARC definitions.
The SEER database recommends to use a 2-month 
period to distinguish between synchronous and meta-
chronous multiple primaries.11 Rules according to the 
IARC suggest the registration of synchronous tumours 
diagnosed in an interval of less than 6 months (or 
metachronous if more than 6 months) if arising in 
different sites.12
Epidemiology of multiple primaries
The burden of second primary malignancies in a growing 
and ageing population of first cancer survivors has 
increased over the last decades.2 Factors accounting for the 
increasing frequency of multiple primaries are improved 
diagnostic tests, increasing and more sophisticated treat-
ment, as well as improved screening and surveillance of 
patients with cancer, for example, screening for colorectal 
and breast cancers.4 9 13–17 Cancer survivors may be suscep-
tible to developing second primary malignancies due to a 
variety of unique factors, including cancer predisposition 
syndromes or special tumour characteristics, environ-
mental exposures and late effects of therapies (table 1). 
Caucasian ancestry, index cancer diagnosed at younger 
age, lower stage and with generally indolent clinical 
behaviour with longer survival, as well as positive family 
history are reported to harbour excess risk for multiple 
primaries.11
The incidence of multiple primaries in a cancer popu-
lation varies between 2.4% and 8%, up to 17% within 20 
years of follow-up (table 2).
The risk of developing a second primary malignancy 
is varying in different cancer sites and is reported in a 
range from 1% (primary liver malignancy) up to 16% 
(primary bladder cancer).18 Weir et al found an incidence 
of multiple primaries of 19.7% following the SEER guide-
lines (or 16.9% IACR rules) in colon and 21% (SEER; 
19.9% IACR) in patients with lung cancer.6 Amer et al 
found similar incidences of multiple primaries in patients 
with colon cancer; however, they only reported 5.6% 
multiple primaries in patients with lung cancer.11
Long-term survival with multiple primaries is variable 
and is influenced by cancer type and stage at diagnosis. 
Genetic factors, behavioural influences, lifestyle and 
comorbidities generally influence patient’s outcomes. In 
Table 1 Epidemiological factors of multiple primary tumours
Epidemiological factors of multiple primaries
Host factors Genetics For example, ancestry, Li-Fraumeni and BRCA mutations
Hormonal factors For example, hormonal therapy and endometrial cancer
Prior cancer diagnosis and 
treatment exposures
The incidence of a second malignancy is higher in a person with a 
previous cancer diagnosis compared with a person of the same age 
group without a prior cancer
Lifestyle factors Alcohol These are risk factors for several cancer types and are therefore more 
likely to develop more than one of these predisposed cancer types 
compared with people without these lifestyle factors
Tobacco
Environmental influences Geography For example, cancer risk in areas of increased radon exposure
Pathogens For example, infections (human papillomavirus, Epstein-Barr virus)
Occupation For example, profession-associated cancer types like mesothelioma 
in workers with asbestos
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general, black patients have a lower incidence of multiple 
primaries and also a lower relative survival independent 
of cancer site or stage at diagnosis (2.37% in black vs 
3.41% white women age-adjusted prevalence for cancer 
survivors in the US population).19 For an overview of 
epidemiological studies, see table 2.
The global cancer burden according to IARC in 2012 
was 14.1 million new cases and 8.2 million cancer deaths 
and is estimated to increase by 2030 to 21.7 million new 
cases and 13 million deaths.20 With this increase alone, 
the number of patients with multiple primaries will grow 
significantly.
In the following short sections, the occurrence of 
multiple primaries in several common cancer types will be 
summarised, not in a systematic approach but to provide 
some ideas of some of the available data on multiple 
primaries. For details and further reading, several good 
reviews are referenced.
Multiple primaries in female patients with breast cancer
Coyte et al assessed the impact of these different defi-
nitions for 8386 women diagnosed with breast cancer. 
Within 5 years after the diagnosis of primary breast cancer, 
a total of 98 secondary breast cancers were diagnosed. 
When applying the SEER guidelines, 79 of the reported 
secondary breast cancers qualified as multiple primaries, 
but according to the IARC/IACR guidelines, it was only 
one case.4
In patients with breast cancer, the incidence of multiple 
primaries has been reported in the range of 4.1% (Kim et 
al 108 patients, 45.9 months follow-up, guideline not avail-
able) to 16.4% (Weir et al 301 963 patients, max. 10 years 
follow-up, SEER, in IACR only 10.4%).6 11 21 The median 
time to a second malignancy was between 5 and 8 years.21 22
Hormonal treatment of a primary breast cancer 
increases the risk for endometrial, gastric, colon and 
ovarian cancers with an excess risk for endometrial cancer 
observed especially after tamoxifen therapy.22
Reproductive/hormonal and genetic factors (eg, 
BRCA1, BRCA2) as well as obesity are recognised as 
common risk factors for multiple primaries (table 3).23
For the breast cancer genes BRCA1 and BRCA2, there 
is a strong association with an increased risk for a second 
breast or ovarian cancer. Furthermore, there is a strong 
association between hereditary gastric cancer and lobular 
breast cancer.9 The risk of a second breast, endometrial or 
ovarian cancer after breast cancer is inversely associated 
Table 2 Incidence of multiple primaries over all cancer sites in the literature
Number of patients 
evaluated Geographic region
Frequency of 
multiple primaries
Mean follow-up
(years)
Definition used for 
multiple primary
(SEER/IACR/IARC) Reference
19 252 Italy 2.4% 2.5 IACR 5
1 015 564 men USA 15.8% NA SEER 6 
951 022 women 14.4% IACR
17.2% SEER
14.55 IACR
334 168 Victoria, Australia 4.3% 5 IACR 8
7.7% 10
12.4% 20
2 919 023 22 European 
countries
6.3% NA IACR 7
57 393 West of Scotland 5% 5 IACR 4
938 Netherlands 7% NA NA 17
1873 USA 7.2% 5 SEER 11
11.4% 10
13.3% 15
14.8% 20
17.2% >20
1953 USA 2.15% 20 NA 14
1 635 060 Italy 6.3% 14 IACR 16
82 671 Switzerland 8.17% 6.6 IACR Authors of this 
publication
IACR, International Association of Cancer Registries; IARC, International Agency for Research on Cancer; SEER, Surveillance Epidemiology 
and End Results.
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with postmenopausal status and history of full-term preg-
nancy.22
Late toxic effects of radiotherapy and chemotherapy also 
contribute to the increased risk for a secondary primary 
tumour after breast cancer. Acute myeloid leukaemia 
(AML) can be induced during the first 2 years after radio-
therapy and is a late effect of adjuvant chemotherapy.22 In 
addition, thyroid cancer, second malignancies of breast, 
bone, connective tissue and lung may arise after radio-
therapy.
Multiple primaries in patients with prostate cancer
Rates of multiple primaries in patients with prostate 
cancer range from 1.14% following radiation therapy 
(Jin et al Meta-analysis from six references, >10 years 
follow-up) to 8.7% (Weir et al 335 565 patients, max. 10 
years follow-up, SEER and IACR).6 24 A systematic review 
with 21 studies evaluating the risk of secondary malignan-
cies in men with prostate cancer who received radiation 
therapy found an increased risk of bladder cancer (HR 
1.67) and colorectal cancer (HR 1.79) with notably an 
increased risk in patients who were treated with external 
beam radiation therapy and no increased risk in men who 
were treated with brachytherapy.25 Radiation therapy has 
been shown to increase the risk for urothelial and rectal 
cancers and sarcomas within the radiation area after 
a disease-free interval of at least 5 years. Increasingly, 
genetic factors accounting for secondary primaries in 
prostate cancer are being recognised, most prominently 
BRCA2 mutations (see also table 5).26
Multiple primaries in patients with Hodgkin’s lymphoma
Multiple primaries rates in patients with Hodgkin’s 
lymphoma are reported in the range of 7.5% (Weir et 
al 13 198 patients, max. 10 years follow-up, SEER and 
IACR) to 7.8% (Bhuller et al 442 patients, up to 39 years 
follow-up)6 27 and are mainly attributed to late toxic treat-
ment effects. Survivors of Hodgkin’s lymphoma with a 
history of radiation therapy have an increased risk for 
breast, lung, thyroid and colorectal cancers.27 28 Chemo-
therapy is associated with an increased risk for secondary 
leukaemias and lung, gastrointestinal or bladder cancer, 
as well as soft tissue and bone sarcomas.9 Secondary 
malignancies are one of the most relevant causes for 
mortality in Hodgkin’s lymphoma survivors.27 Secondary 
leukaemia and myelodysplastic syndromes are associated 
with combination chemotherapy, especially etoposide in 
a dose-dependent manner. Etoposide-related leukaemia 
is distinguished from other forms of leukaemia that can 
be induced by alkylating agents by characteristics such 
as a shorter time from the end of treatment to develop-
ment of leukaemia and evidence of translocation 11q23 
or 21q22.29
Multiple primaries in patients with lung cancer
In patients with lung cancer, the incidence of multiple 
primaries ranges from 13.4% (Rosso et al 2 919 023 
patients, follow-up not available, IACR) to 22% (Sánchez 
et al 1769 patients, 5–23 years follow-up, only patients 
with survival >3 years (12.3%)).7 Patients diagnosed with 
early stage lung cancer have an increased risk for second 
primaries compared with the general population without 
a prior cancer diagnosis.30 Many second malignancies 
are related to smoking. The rate of second primaries 
is slightly lower in first primary adenocarcinoma with a 
rate of 3.36 per 100 person-years than in squamous cell 
carcinoma with a rate of 3.77 per 100 person-years. It is 
highest in small cell lung cancer (SCLC) with 4.46 cases 
per 100 person-years. There is no significant association 
with radiotherapy.30
The most common second cancers are in the lung, 
especially if the first primary was a SCLC. The most 
common second lung malignancies are adenocarcinomas 
(29.9%) followed by squamous cell carcinomas (27.1%). 
SCLCs represent only 7.9% of the second pulmonary 
malignancies after a first lung cancer.31 Also, colorectal 
and bladder cancers are often found as second malignan-
cies after a primary lung cancer.
Summary on epidemiology of multiple primaries
 ► Multiple primaries are defined as more than one 
synchronous or metachronous cancer in the same 
individual.
 ► Synchronous and metachronous multiple primaries 
are distinguished. Definitions depend on whether 
SEER or the IACR/IARC rules are applied.
 ► Common risk factors for multiple primaries are as 
follows: inherited predisposition to cancer; cancer-
Table 3 Common risk factors for multiple primaries in women with breast cancer (adapted from Wood et al9)
Second cancer Risk factors
Second breast cancer Genetic (BRCA1, BRCA2) Endocrine/hormonal factors Obesity
Ovarian Genetic (BRCA1, BRCA2) Endocrine/hormonal factors
Uterine/endometrial Endocrine/hormonal factors Obesity
Colorectal cancer Endocrine/hormonal factors Obesity
Renal cell carcinoma Obesity
Pancreatic Obesity
Thyroid Obesity
Gallbladder Obesity
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promoting aspects of lifestyle, hormonal and 
environmental factors; treatment of the previous 
primary cancer and increased surveillance of cancer 
survivors.32
 ► The incidence of multiple primaries varies in 
different primary cancer types and treatment that 
was applied for these cancers.
Cancer predisposition syndromes and genetic test-
ing
Several clinical scenarios should call a clinician’s atten-
tion towards the possibility of an underlying cancer 
predisposition, in particular the occurrence of multiple 
primary cancers, diagnosis at young age and in several 
family members. For example, metachronous breast and 
ovarian cancers, especially in younger patients, should 
prompt evaluation of an underlying hereditary breast and 
ovarian cancer (HBOC) syndrome associated with germ-
line mutations in the BRCA1/2 genes, likewise prostate 
cancer in a young male patient with a family history of 
breast cancer and melanoma. Similarly, colon cancer in 
a young woman from a colon and endometrial cancer-
prone family points towards Lynch syndrome (LS) (see 
also table 4 for further clinical scenarios).
Also, in the era of novel targeted agents and check-
point inhibitors, germline and somatic mutations are 
becoming more important with respect to new treatment 
options and strategies, such as the use of poly-ADP-ribose 
polymerase (PARP) inhibitors in patients whose tumours 
display DNA repair defects (BRCA1/2, ATM) or check-
point inhibitors in tumours with high mutational load 
as exemplified by microsatellite instability (MSI). This 
has opened another field for direct-to-consumer genetic 
testing, which is increasingly being offered by commer-
cial companies through internet portals and has risen 
widespread concerns about accuracy, usefulness and 
interpretation of such tests in the absence of medical 
supervision and genetic counselling.29 33 In the following, 
we will give a short, non-comprehensive overview of the 
most relevant cancer predispositions in routine oncology 
care, namely HBOC, LS (formerly known as hereditary 
non-polyposis colon cancer, HNPCC), multiple endocrine 
neoplasia type 1 and type 2 (MEN1, MEN2), von Hippel-
Lindau (VHL) disease and Li-Fraumeni syndrome (LFS). 
For a more detailed overview, we recommend the review 
by Garber and Offit34 as well as the ESMO guidelines on 
hereditary cancer syndromes.35 36
Hereditary breast and ovarian cancer syndrome
HBOC is a high-penetrance, autosomal-dominant breast 
and ovarian cancer predisposition caused by germline 
mutations in the genes BRCA1 and BRCA2. Its prevalence 
in an unselected population is estimated to be <10% but is 
markedly increased (up to 35%) in patients with a positive 
family history of breast and ovarian cancers, young age 
at first diagnosis, multiple metachronous breast/ovarian 
tumours or special ethnic groups (Ashkenazi Jews). 
The average lifetime risk for breast or ovarian cancer in 
BRCA1 and BRCA2 carriers by age 80 is up to ca. 83% and 
76%, respectively;37 for men with BRCA2 mutation, life-
time risk for breast and prostate cancers is also elevated 
(up to ca. 8.9%). Criteria for genetic counselling and 
testing referral vary between countries, but commonly 
include clinical features (see table 4) as well as predictive 
models such as BRCAPRO or Manchester Score. However, 
with higher awareness and apart from surveillance also 
emerging therapeutic consequences as PARP inhibitors, 
more widespread testing can be expected.
Lynch syndrome/hereditary non-polyposis colon cancer
In this autosomal-dominantly inherited cancer predis-
position, germline loss-of-function mutations in DNA 
mismatch repair (MMR) genes combined with a second, 
somatically acquired hit in the tumour lead to MSI and 
a mutated phenotype resulting in an increased risk for 
colon and endometrial cancers as well as more rarely to 
cancers, for example, of the urinary tract, ovary, small 
intestine, gastric and hepatobiliary tract.38 39 In the overall 
colon cancer population, the prevalence for LS is approx. 
1–3% and lifetime risk in MMR gene mutation carriers 
for colon and endometrium cancers amounts to approx. 
52–82% and 25–60%, respectively.40 41 Referral for genetic 
counselling and testing is generally based on MSI immu-
nohistochemistry results on patient’s tumour tissue in 
conjunction with family history. As with BRCA1/2-asso-
ciated cancers, MSI (sporadic and germline) recently 
gained more attention due to possible therapeutic conse-
quences, as was shown, that checkpoint inhibitors seem 
to be effective almost exquisitely in colon and gastric 
cancers with MSI high tumours.42
von Hippel-Lindau disease
VHL disease is an autosomal dominantly inherited 
tumour predisposition syndrome, which is associated with 
an increased risk of developing various benign and malig-
nant tumours, including retinal capillary and central 
nervous system haemangioblastomas, phaeochromocy-
tomas, renal cysts and clear cell renal cell carcinomas, 
endolymphatic sac tumours as well as pancreatic cysts, 
pancreatic neuroendocrine tumours and cystadenomas 
of the epididymis and the broad ligament.43 The disease 
penetrance is high and more than 90% of patients 
harbouring a VHL mutation develop clinical symp-
toms before the age of 65 years. Disease expression and 
severity vary considerably within and between families.44 
Preventive screening programmes have improved median 
overall survival of affected patients.
Li-Fraumeni syndrome
Caused by germline mutations in the ‘guardian of the 
genome’, the tumour protein p53 (TP53) gene, LFS 
is characterised by a distinct set of early onset tumours 
such as sarcoma, breast cancer, brain tumours, leukaemia 
and adrenocortical carcinoma. Due to the rarity of the 
syndrome until now, no standard surveillance protocols 
have been implemented, but recent studies could show 
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Table 4 Clinical scenarios and potential genetic cancer syndrome
Clinical picture, patient with 
a history or diagnosis of 
(synchronous or metachronous) Familial cancer syndrome to think of Full picture of familial cancer syndrome
Synchronous bilateral 
breast cancer or secondary 
(metachronous) breast cancer
Hereditary breast and ovarian cancer 
(HBOC) [BRCA1, BRCA2]
•Breast cancer
•Ovarian cancer
Breast and ovarian cancers HBOC [BRCA 1/2] •Male breast cancer
Prostate cancer and pancreatic 
cancer or melanoma
HBOC [BRCA 2] •Prostate cancer
•Melanoma
(Multiple) renal cell carcinomas VHL •Renal cell carcinoma <47 years
Renal cell carcinoma and 
pancreatic cystic lesions
VHL •Multiple renal cysts
Haemangioblastomas of central 
nervous system (CNS) and retina
VHL •Multiple pancreas cysts and pancreatic 
neuroendocrine tumour
•CNS and retinal haemagioblastomas
•Phaeochromocytomas
•Endolymphatic sac tumours
•Cystadenomas of epididymis or broad 
ligament
Breast cancer and sarcoma Li-Fraumeni syndrome •Soft tissue sarcoma and osteosarcoma
Breast cancer and leukaemia Li-Fraumeni syndrome •Premenopausal breast cancer
•Leukaemia
•Brain tumours
•Adrenocortical carcinoma
•Lung bronchoalveolar cancer
Colon and endometrial cancers Lynch syndrome •Colon cancer
Colon and ovarian cancers HNPCC •Endometrial cancer
 •Ovarian cancer
•Renal pelvis cancers
•Ureteral cancers
•Pancreatic and hepatobiliary cancers
•Stomach and small bowel cancers
Multiple colon polpys and/or colon 
cancer
Familial adenomatous polyposis •Colon cancer
•Duodenal cancer
•Thyroid cancer
•Hepatoblastoma
Parathyroid adenomas and 
pituitary adenomas
MEN1 •Pituitary tumours
•Parathyroid tumours
•Endocrine tumours of the gastro–entero–
pancreatic tract
•Carcinoid tumours
Medullary thyroid cancer and 
phaeochromocytoma
MEN 2 •Medullary thyroid cancer
•Phaeochromocytoma
Continued
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long-term survival benefit for patients complying with an 
intensive surveillance protocol for early tumour detec-
tion.45
MEN1/MEN2 syndrome
Basis of the autosomal dominantly inherited MEN1 
syndrome are germline mutations in the MEN1 
gene, predisposing to parathyroid adenomas, pitu-
itary adenomas and pancreatic islet cell tumours as 
gastrinomas, vipomas or insulinomas.46 Surveillance of 
mutation carriers should start at an early age, usually 
between 5 and 10 years. MEN2 is associated with medul-
lary thyroid cancer and phaeochromocytoma and in 
nearly 90% of affected patients a germline RET-proto-onco-
gene mutation can be found.47
CLINICAL SITUATIONS WHEN TO SUSPECT MULTIPLE 
PRIMARIES (SYNCHRONOUS OR METACHRONOUS)
As discussed above, multiple primaries can occur in a 
synchronous or metachronous pattern. In the situation of a 
new cancer diagnosis, staging examinations are performed 
to assess the extent of disease but sometimes also to localise 
a primary tumour in the situation where a metastatic site is 
the first presentation of malignancy. In patients with a prior 
cancer diagnosis, often over the period of several years, 
follow-up tests and examinations are performed in order to 
rule out relapse.
With the increasing use of more sophisticated imaging 
methods, namely positron-emission tomography 
computed tomography (PET-CT) and whole body MRI, 
it is not uncommon to find suspicious lesions that might 
have not been detected by standard CT and/or bone 
scintigraphy. In a large series of 1912 patients who were 
scanned with PET-CT scans, lesions suspicious of addi-
tional malignant tumour were found in 4.1% of which 
1.2% were histologically confirmed.48 Not surprisingly, 
these secondary primaries were in the following localisa-
tions: thyroid, colon, breast, oesophagus, bile duct and 
head and neck regions, where even contrast enhanced CT 
may easily miss small tumours. In a series of 200 patients 
with oesophageal cancer who underwent PET-CT for 
staging, a total of 17% patients had synchronous multiple 
primary tumours, namely in the stomach, head and neck 
regions, colon and lung.49
Several clinical features should alert clinicians to the 
possibility that a patient may have a second primary 
tumour both synchronous and in the situation of a prior 
cancer history:
 ► Atypical metastatic spread of primary tumour (eg, 
radiologically lytic bone metastases in prostate 
cancer).
 ► High tumour burden relative to tumour marker load 
(eg, extensive liver metastases with low prostate-
specific antigen in prostate cancer).
 ► New metastatic spread (eg, liver, lung) several years 
after a primary cancer diagnosis.
 ► Single new metastatic lesion after a primary cancer 
diagnosis (eg, single pulmonary nodule in a patient 
with a prior primary head and neck carcinoma).
 ► Chronological atypical metastatic spread (eg, relapse 
5 years after primary small cell carcinoma of the 
lung).
 ► Recurrence in patients with exposure to 
environmental carcinogens (eg, smoking).
 ► Suspicion of haematological malignancy after prior 
chemotherapy (eg, etoposide, anthracyclines).
 ► Suspicion of secondary malignancy in patients with 
prior radiation for malignancy and especially if 
recurrence in prior radiation field.
 ► Suspicious lesion on imaging (eg, PET-CT) detected 
at staging or in follow-up.
 ► Differential standard uptake value (SUV) of 
suspected lesions on PET-CT (eg, lesions with very 
high SUV and lesions with low SUV).
In case of a suspected secondary primary, a histological 
confirmation should be pursued if the patient is consid-
ered for active treatment. With the advances in imaging 
and imaging-guided biopsy techniques, it is in most cases 
possible to get enough tissue for an adequate diagnosis. 
Importantly, the primary tissue should always be available 
for comparison, especially in cases of undifferentiated 
histologies and clinicians should inform the reporting 
pathologist about the fact that a primary cancer diagnosis 
has already been established. In case of a new diagnosis in 
a patient with multiple metastatic sites, the collection of 
more than one biopsy has to be considered.
TREATMENT APPROACHES IN PATIENTS WITH MULTIPLE 
PRIMARIES
Synchronous multiple primaries
The treatment of patients with synchronous multiple 
primaries is challenging and often a therapeutic dilemma. 
In table 5, a few examples of patients with synchronous 
multiple primaries are summarised to illustrate the diffi-
culties that arise in daily clinical practice. Patients with 
Clinical picture, patient with 
a history or diagnosis of 
(synchronous or metachronous) Familial cancer syndrome to think of Full picture of familial cancer syndrome
•Parathyroid hyperplasia/adenoma
HNPCC, hereditary non-polyposis colon cancer; MEN1, multiple endocrine neoplasia type 1; MEN2, multiple endocrine neoplasia type 2; 
VHL, von Hippel-Lindau.
Table 4 Continued 
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synchronous multiple primaries should be discussed in 
multidisciplinary team (MDT) meetings and a consensus 
on a therapeutic strategy can sometimes take more than 
one MDT to form. Also, the patient should be informed 
about the situation and therapeutic challenges and often 
the uncertainty about the prognosis, because the therapy 
approach needs to be adapted.
In localised disease, the strategy may be surgery or 
radiation/chemoradiation therapy covering both malig-
nancies.50 51
However, in the situation of advanced disease, the 
antitumour therapy selection is often difficult and 
mostly not based on evidence from the literature and 
clinical trials. In patients where both tumours are likely 
to respond to the same antitumour regimen as may be 
the case in patients with synchronous squamous cell 
carcinoma of the head and a second head and neck or 
squamous non-small cell lung cancer, the therapeutic 
decision will involve a systemic therapy, which is likely 
to be active in for example, a platinum-based chemo-
therapy.
In patients with synchronous multiple primaries, the 
following points should be considered when deciding 
on an antitumour treatment strategy. Please note that 
the proposed approaches are individual decisions and 
not general treatment recommendations. Also, these 
treatment approaches are not based on prospective trial 
evidence but rather ‘real-world’ examples of challenging 
clinical situations.
 ► What is the most significant tumour in terms 
of prognosis? Is there any chance of a curative 
approach or is the situation palliative? If palliative, 
which tumour is metastasised, what is known about 
the tumour dynamics (imaging, tumour marker) of 
Table 5 Examples of clinical cases of patients with synchronous advanced multiple primary tumours
Patient 
characteristics Malignancy 1 Malignancy 2 Therapeutic dilemma
Current management 
strategy
60-year-old man, 
former smoker
Small cell lung 
cancer (SCLC)
Progression: after 6 
cycles of cisplatin/
etoposide
Aplastic anaemia
Diagnosed 4 months 
after completion of 
cisplatin/etoposide
•Chemotherapy at 
progression of SCLC 
not possible due to 
grade 4 neutropenia and 
thrombocytopenia in the 
setting of aplastic anaemia
•Immunosuppressive therapy 
for aplastic anaemia with 
possible negative impact on 
SCLC
•Supportive treatment 
with eltrombopag for 
thrombocytopenia
•In case of stabilisation of 
pancytopenia, evaluation of 
second line therapy for SCLC
71-year-old 
man, hereditary 
haemochromatosis
Castration-resistant 
prostate cancer with 
bone and lymph 
node metastases
Renal cell carcinoma 
with lung metastases
•Drugs active in for CRPC 
different than agents in RCC
•TKI used for RCC endocrine 
drugs (abiraterone/
enzalutamide) used for 
CRPC: combinations 
not tested, no safety 
data, possible drug–drug 
interactions, expensive 
combinations
•Alternating treatment for 
the two malignancies: for 
example, TKI for 3–4 months 
for mRCC, then interruption 
and treatment for mCRPC for 
3–4 months depending on the 
most significant tumour
64-year-old man, 
former smoker
Non-small cell lung 
cancer (NSCLC) 
stage IIIB
Rectal cancer stage I •Chemotherapy regimens 
active in NSCLC generally 
not active in rectal cancer
•NSCLC stage IIIB 
prognosis-defining, but 
untreated rectal cancer 
bears high risk of local 
complications (eg, bowel 
obstruction)
•Curative resection of rectal 
cancer (node-negative) with 
protective colostomy
•Chemoradiation with 
curative intent for NSCLC 
(IIIB)
65-year-old woman, 
former smoker
NSCLC, metastatic 
to lymph nodes and 
bone,
KRAS proto-
oncogene 
(KRAS)-mutated, 
programmed death 
receptor ligand (PD-
L1) expression 0%
Acute myeloid 
leukaemia (AML)
Diagnosed 
simultaneously with 
NSCLC
•Chemotherapy for NSCLC 
not possible due to grade 4 
neutropenia in the setting of 
AML
•State-of-the art treatment 
for AML in the setting of 
metastatic NSCLC
•Treatment with azacitidin for 
AML
•In case of stabilisation of 
AML, evaluation of treatment 
for NSCLC (checkpoint 
inhibitor rather than 
chemotherapy due to limited 
bone marrow reserve)
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the synchronous multiple primaries? What are the 
systemic therapy options?
 ► Should treatment strategy focus on local or systemic 
therapy? Can one of the synchronous tumours be 
treated radically and then the second malignancy 
sequentially?
 ► Which problems can be anticipated? For example, 
bowel obstruction in untreated colorectal cancer, 
liver failure in case of extensive liver metastases.
 ► If systemic therapy is necessary for, for example, two 
advanced malignancies, can a regimen be chosen 
that is active for both diagnoses? If not, what is the 
potential of interaction between two antitumour 
regimens (hepatic, eg, cytochrome-P (CYP) or 
cardiac frequency-corrected QT interval on the 
ECG)? Is there any literature about the combination 
(eg, axitinib and enzalutamide (see table 5))? 
Can systemic chemotherapy for an advanced 
solid tumour be applied at all (eg, in the case of 
secondary malignancy in the form of AML)? Can the 
two malignancies be treated in a cycling manner (eg, 
systemic treatment for tumour A for 2–3 months, 
followed by systemic therapy for tumour B)?
 ► Tumour profiling: Can the tumours be profiled 
(eg, targeted panel sequencing) and could these 
tumours have a common genetic background, which 
allows a common strategy option (eg, synchronous 
malignancies in BRCA1/2 carriers)?
Importantly, patients with active secondary malignancy 
are excluded from the vast majority of clinical trials 
involving novel treatments. For the majority of situations 
of patients with synchronous multiple primaries, only case 
reports are available in the literature and these should be 
applied to an individual clinical situation with caution.
Metachronous multiple primaries
The situation of metachronous multiple primaries can 
be equally challenging. For the situation when the first 
malignancy is still active/advanced, the considerations 
above apply. For the situation where a tumour was treated 
with curative intent and where a biopsy has confirmed a 
metachronous second malignancy, several points should 
be considered:
 ► Can the second primary cancer be treated with 
curative intent?
 ► What prior treatment has the patients had for the 
prior cancer diagnosis?Prior surgery: For example, 
in breast cancer? Is a second breast-conserving 
surgery possible and reasonable? In lung cancer: 
Is a second lung operation possible?Prior radiation 
therapy: Is there any overlap with the prior radiation 
field? Could the second primary be radiation 
therapy induced? What is the tolerance of the 
healthy tissue in the previously irradiated area? 
What is the radiation reserve and does it allow a 
radiation therapy with curative intent or only a 
palliative schedule/dose?Prior systemic therapy: 
What regimen? How long since the last systemic 
therapy? What cumulative dose (eg, anthracyclines)? 
Is there any residual toxicity (eg, neuropathy, bone 
marrow toxicity)? Is the second primary potentially 
treatment induced?
 ► Can any possible complications be anticipated based 
on the patient’s prior anticancer therapy history?
 ► Are there carcinogenic factors that can be managed? 
For example, smoking, alcohol, viral infection.
 ► Could a cancer predisposition explain the multiple 
primaries?
As discussed in the sections above, the number of 
multiple metachronous tumours is likely to increase. 
Currently, the literature on the management of patients 
with metachronous multiple primaries is scarce, but it will 
be important to collect the information possibly through 
cancer registries in order to learn and identify potential 
rare complications in these situations.
DISCUSSION AND CONCLUSION
Based on a combination of factors (diagnosis, treatment, 
demographics), it is expected that in the course of the 
coming years, the prevalence of patients with multiple 
primaries will increase. In the literature, depending on 
definition, the frequency of multiple primaries ranges 
between 2.4% and 17% and it is important to realise that 
with longer follow-up the number of multiple primaries 
increases in all studies significantly and also that most of 
the epidemiological studies are based on data acquired 
more than 10 years ago and that therefore with longer 
follow-up or in subsequent studies the percentage of 
patients with synchronous but mainly metachronous 
multiple primaries will increase.
Also, it is important to recognise that certain patient popu-
lations are at higher risk of developing multiple primaries, 
namely male patients and patients with a history of smoking 
or alcoholism but also patients diagnosed with a primary 
malignancy at an early stage and lower grade and patients 
with a hereditary cancer syndrome. Also, the number of 
octogenarians diagnosed with cancer is increasing and at 
the same time the frequency of multiple primaries in older 
patients who are potentially fit enough to receive active 
antineoplastic therapy.
Treatment-related secondary malignancies as observed 
in patients with germ cell or Hodgkin’s lymphoma are 
well characterised but with novel targeted therapies it is 
currently unclear whether an increased rate of secondary 
malignancies needs to be taken into consideration. For 
the B-RAF (rapidly accelerated fibrosarcoma) inhibitor 
vemurafenib, an increased rate of secondary cutaneous 
malignancies was demonstrated and requires careful 
and regular dermatological evaluation for patients 
on treatment.52 Also, for the PARP inhibitor olaparib, 
cases of myelodysplastic syndromes and AML have been 
observed and careful monitoring of patients for haemato-
logical toxicity is recommended.53
With the advances and wider availability of genetic 
testing (eg, gene panels), patients diagnosed with 
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multiple primaries will be increasingly investigated for an 
underlying cancer predisposition. The gain of knowledge 
on patients with hereditary cancer and cancer survivors 
will hopefully allow the development of specific manage-
ment and surveillance measures.
For clinical trials, generally patients with secondary 
malignancies are very often excluded unless they have 
been low grade/stage and were successfully treated at 
least 3-5 years ago. To reflect more of a real life population 
and to enable patients with a prior cancer history partic-
ipation in clinical trials, the exclusion criteria, especially 
for early phase clinical trials could be modified to only 
exclude patients who currently require active anticancer 
therapy. Admittedly, this may add marked complexity in 
assessing efficacy and progression and may therefore not 
be suitable for phase III clinical trials.
Further research is needed, especially with regards to 
the areas of the treatment of patients with synchronous or 
metachronous multiple primary cancers. Also, the impact 
of prior therapies on prognosis, antitumour efficacy and 
toxicity needs to be better characterised.
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